Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
Whitney E. Lewis, Lingzhi Hong, Frank E. Mott, George R. Simon, Carol C. Wu, Waree Rinsurongkawong, J. Jack Lee, Vincent K. Lam, John V. Heymach, Jianjun Zhang, Xiuning Le
Abstract
INTRODUCTION: -rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. METHODS: alterations. RESULTS: = 0.04) alterations. CONCLUSIONS: alterations occur in patients with LUSC, especially never-smoker females. TKI treatments render clinical benefit in disease control, but the duration was considerably truncated compared with those historically observed in LUAD.
Topics & Concepts
MedicineKRASLung cancerAdenocarcinomaInternal medicineOncologyGefitinibEpidermal growth factor receptorErlotinibCancerCancer researchColorectal cancerLung Cancer Treatments and MutationsCholangiocarcinoma and Gallbladder Cancer StudiesRNA modifications and cancer